Imvotamab  (Synonyms: IGM-2323)

Imvotamab (IGM-2323) is a CD20 and CD3 bispecific IGM antibody with dual action mechanism. Imvotamab is used to induce physiological T cell activation to prevent over-stimulation and subsequent down-regulation of immune function. Imvotamab can be used for the study of B-cell malignant tumors, multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL)^[1][2][3][4].

CD3E

Imvotamab (1-10000 pM) has Killing effect on Rituximab (HY-P9913)-resistant ramos cells^[5].
Imvotamab (0.1-1000 pM) has Killing effect on standard ramos cells^[5].
Imvotamab (1-1000 pM) significantly reduces the content of IL-6, IL-2, IFNγ and TNFα in cytokine release syndrome^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Imvotamab (0.001-10 mg/kg; single dose) significantly reduces the percent of B cells in cynomolgus monkeys^[5].
Imvotamab (25 mg/kg) promotes the depletion of B cells in spleen and lymphoid tissue without significant adverse effects in non-human primate^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2573121-53-4

[Imvotamab]

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgM-kappa-[scFv-heavy-kappa]-Jchain-ALB

• [1]. Hernandez G H, et al. Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies[J]. Blood, 2022, 140(Supplement 1): 6436-6438.

  [2]. Li K, et al. Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety Profile[J]. Blood, 2022, 140(Supplement 1): 6010-6011.

  [3]. Budde E, et al. Preliminary results of a phase 1 dose escalation study of the first-in-class IgM based bispecific antibody Igm-2323 (anti-CD20 x anti-CD3) in patients with advanced B-cell malignancies[J]. Blood, 2020, 136: 45-46.

  [4]. Hart K C, et al. High valency of IGM-2323, a CD20xCD3 IgM bispecific T cell engager, displaces rituximab binding and induces potent B lymphoma cell killing[J]. Cancer Research, 2022, 82(12_Supplement): 4179-4179.

  [5]. Baliga R, et al. A Bispecific IgM Antibody Format for Enhanced T cell-Dependent Killing with Minimal Cytokine Release[J]. Cancer Res, 2020, 80(16 Supplement): 5664-5664.